Cooperation between RUNX1-ETO9a and Novel Transcriptional Partner KLF6 in Upregulation of Alox5 in Acute Myeloid Leukemia

PLoS Genetics

Volumn 9, Issue 10, 2013, Pages

  DeKelver, Russell C ^a   Lewin, Benjamin ^a   Lam, Kentson ^b   Komeno, Yukiko ^c   Yan, Ming ^c   Rundle, Chandler ^a   Lo, Miao Chia ^c   Zhang, Dong Er ^a,b,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AF9 PROTEIN; BCR ABL PROTEIN; ETO9A PROTEIN; HYBRID PROTEIN; KRUPPEL LIKE FACTOR 6; MIXED LINEAGE LEUKEMIA PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID RECEPTOR ALPHA; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALOX5 GENE; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CONTROLLED STUDY; EMBRYO; FETUS; GENE; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE LOSS; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; UPREGULATION;

ALTERNATIVE SPLICING; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LEUKEMIA, MYELOID, ACUTE; MICE; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION FACTORS;

EID: 84887286522     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1003765     Document Type: Article

References (55)

1. National Cancer Institute (2013) Adult Acute Myeloid Leukemia Treatment. http://www.cancer.gov/cancertopics/pdq/treatment/adultAML Accessed April 3, 2013.
2. Rowe D, Cotterill SJ, Ross FM, Bunyan DJ, Vickers SJ, et al. (2000) Cytogenetically cryptic AML1-ETO and CBF beta-MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemia. Br J Haematol 111: 1051-1056.
3. Groupe Francais de Cytogenetique Hematologique (1990) Acute myelogenous leukemia with an 8;21 translocation. A report on 148 cases from the Groupe Francais de Cytogenetique Hematologique. Cancer Genet Cytogenet 44: 169-179.
4. Nucifora G, Rowley JD, (1995) AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 86: 1-14.
5. Langabeer SE, Walker H, Rogers JR, Burnett AK, Wheatley K, et al. (1997) Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials. MRC Adult Leukaemia Working Party. Br J Haematol 99: 925-928.
6. Rege K, Swansbury GJ, Atra AA, Horton C, Min T, et al. (2000) Disease features in acute myeloid leukemia with t(8;21)(q22;q22). Influence of age, secondary karyotype abnormalities, CD19 status, and extramedullary leukemia on survival. Leuk Lymphoma 40: 67-77.
7. Peterson LF, Boyapati A, Ahn EY, Biggs JR, Okumura AJ, et al. (2007) Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. Blood 110: 799-805.
8. Muller AM, Duque J, Shizuru JA, Lubbert M, (2008) Complementing mutations in core binding factor leukemias: from mouse models to clinical applications. Oncogene 27: 5759-5773.
9. Mulloy JC, Cammenga J, Berguido FJ, Wu K, Zhou P, et al. (2003) Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood 102: 4369-4376.
10. Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, et al. (2006) A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med 12: 945-949.
11. Kozu T, Fukuyama T, Yamami T, Akagi K, Kaneko Y, (2005) MYND-less splice variants of AML1-MTG8 (RUNX1-CBFA2T1) are expressed in leukemia with t(8;21). Genes Chromosomes Cancer 43: 45-53.
12. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, et al. (1998) Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 18: 7185-7191.
13. Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, et al. (1998) ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 18: 7176-7184.
14. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM, (1998) ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A 95: 10860-10865.
15. Hines R, Boyapati A, Zhang DE, (2007) Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO. Blood Cells Mol Dis 39: 297-306.
16. Ptasinska A, Assi SA, Mannari D, James SR, Williamson D, et al. (2012) Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. Leukemia 26: 1829-1841.
17. Martens JH, Mandoli A, Simmer F, Wierenga BJ, Saeed S, et al. (2012) ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood 120: 4038-4048.
18. Lo MC, Peterson LF, Yan M, Cong X, Jin F, et al. (2012) Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML. Blood 120: 1473-1484.
19. Wang L, Gural A, Sun XJ, Zhao X, Perna F, et al. (2011) The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 333: 765-769.
20. Shia WJ, Okumura AJ, Yan M, Sarkeshik A, Lo MC, et al. (2012) PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential. Blood 119: 4953-4962.
21. Tong WG, Ding XZ, Talamonti MS, Bell RH, Adrian TE, (2005) LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochem Biophys Res Commun 335: 949-956.
22. Kim EY, Seo JM, Cho KJ, Kim JH, (2010) Ras-induced invasion and metastasis are regulated by a leukotriene B4 receptor BLT2-linked pathway. Oncogene 29: 1167-1178.
23. Kim GY, Lee JW, Cho SH, Seo JM, Kim JH, (2009) Role of the low-affinity leukotriene B4 receptor BLT2 in VEGF-induced angiogenesis. Arterioscler Thromb Vasc Biol 29: 915-920.
24. Mezhybovska M, Wikstrom K, Ohd JF, Sjolander A, (2006) The inflammatory mediator leukotriene D4 induces beta-catenin signaling and its association with antiapoptotic Bcl-2 in intestinal epithelial cells. J Biol Chem 281: 6776-6784.
25. Rioux N, Castonguay A, (1998) Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis 19: 1393-1400.
26. Hennig R, Ventura J, Segersvard R, Ward E, Ding XZ, et al. (2005) LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice. Neoplasia 7: 417-425.
27. Pidgeon GP, Lysaght J, Krishnamoorthy S, Reynolds JV, O'Byrne K, et al. (2007) Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev 26: 503-524.
28. Chung JW, Kim GY, Mun YC, Ahn JY, Seong CM, et al. (2005) Leukotriene B4 pathway regulates the fate of the hematopoietic stem cells. Exp Mol Med 37: 45-50.
29. Chen Y, Hu Y, Zhang H, Peng C, Li S, (2009) Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet 41: 783-792.
30. Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, et al. (1981) Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood 58: 1203-1212.
31. Roboz GJ, (2012) Current treatment of acute myeloid leukemia. Curr Opin Oncol 24: 711-719.
32. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, et al. (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116: 354-365.
33. Matsumoto N, Kubo A, Liu H, Akita K, Laub F, et al. (2006) Developmental regulation of yolk sac hematopoiesis by Kruppel-like factor 6. Blood 107: 1357-1365.
34. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, van Waalwijk van DoornKhosrovani Barjesteh, et al. (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350: 1617-1628.
35. Silverman ES, Le L, Baron RM, Hallock A, Hjoberg J, et al. (2002) Cloning and functional analysis of the mouse 5-lipoxygenase promoter. Am J Respir Cell Mol Biol 26: 475-483.
36. Juven-Gershon T, Kadonaga JT, (2010) Regulation of gene expression via the core promoter and the basal transcriptional machinery. Dev Biol 339: 225-229.
37. Zhao JL, Austen KF, Lam BK, (2000) Cell-specific transcription of leukotriene C(4) synthase involves a Kruppel-like transcription factor and Sp1. J Biol Chem 275: 8903-8910.
38. Cao Z, Sun X, Icli B, Wara AK, Feinberg MW, (2010) Role of Kruppel-like factors in leukocyte development, function, and disease. Blood 116: 4404-4414.
39. Botella LM, Sanchez-Elsner T, Sanz-Rodriguez F, Kojima S, Shimada J, et al. (2002) Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood 100: 4001-4010.
40. Wei H, Liu X, Xiong X, Wang Y, Rao Q, et al. (2008) AML1-ETO interacts with Sp1 and antagonizes Sp1 transactivity through RUNT domain. FEBS Lett 582: 2167-2172.
41. Liu Y, Chen W, Gaudet J, Cheney MD, Roudaia L, et al. (2007) Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity. Cancer Cell 11: 483-497.
42. Dekelver RC, Yan M, Ahn EY, Shia WJ, Speck NA, et al. (2013) Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential. Blood 121: 3714-7.
43. Swansbury GJ, Slater R, Bain BJ, Moorman AV, Secker-Walker LM, (1998) Hematological malignancies with t(9;11)(p21-22;q23)-a laboratory and clinical study of 125 cases. European 11q23 Workshop participants. Leukemia 12: 792-800.
44. Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, et al. (1994) Acute promyelocytic leukemia: from genetics to treatment. Blood 83: 10-25.
45. Kuo YH, Landrette SF, Heilman SA, Perrat PN, Garrett L, et al. (2006) Cbf beta-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia. Cancer Cell 9: 57-68.
46. de Guzman CG, Warren AJ, Zhang Z, Gartland L, Erickson P, et al. (2002) Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol 22: 5506-5517.
47. Tam WF, Hahnel PS, Schuler A, Lee BH, Okabe R, et al. (2013) STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2. Cancer Res 73: 373-384.
48. Peng C, Chen Y, Shan Y, Zhang H, Guo Z, et al. (2012) LSK derived LSK- cells have a high apoptotic rate related to survival regulation of hematopoietic and leukemic stem cells. PLoS One 7: e38614.
49. Benz C, Copley MR, Kent DG, Wohrer S, Cortes A, et al. (2012) Hematopoietic stem cell subtypes expand differentially during development and display distinct lymphopoietic programs. Cell Stem Cell 10: 273-283.
50. Peterson LF, Zhang DE, (2004) The 8;21 translocation in leukemogenesis. Oncogene 23: 4255-4262.
51. Ahn EY, Dekelver RC, Lo MC, Nguyen TA, Matsuura S, et al. (2011) SON Controls Cell-Cycle Progression by Coordinated Regulation of RNA Splicing. Mol Cell 42: 185-198.
52. Chen XS, Sheller JR, Johnson EN, Funk CD, (1994) Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 372: 179-182.
53. Peterson LF, Wang Y, Lo MC, Yan M, Kanbe E, et al. (2007) The multi-functional cellular adhesion molecule CD44 is regulated by the 8;21 chromosomal translocation. Leukemia 21: 2010-2019.
54. Meyers S, Downing JR, Hiebert SW, (1993) Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol 13: 6336-6345.
55. Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, et al. (2005) A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res 65: 1213-1222.